Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

• Published in: The Journal of infectious diseases Vol. 177; no. 2; pp. 310 - 309
• Main Authors: Graham, Barney S., McElrath, M. Juliana, Connor, Ruth I., Schwartz, David H., Gorse, Geoffrey J., Keefer, Michael C., Mulligan, Mark J., Matthews, Thomas J., Wolinsky, Steven M., Montefiori, David C., Vermund, Sten H., Lambert, John S., Corey, Lawrence, Belshe, Robert B., Dolin, Raphael, Wright, Peter F., Korber, Bette T., Wolff, Mark C., Fast, Patricia E.
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.02.1998; University of Chicago Press
• Subjects: AIDS; AIDS vaccines; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; HIV; HIV 1; HIV infections; Infections; Lymphocytes; Major Articles; Microbiology; Placebos; Vaccination; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Virology; Viruses; Human; Immunopathology; Immune response; HIV-1 virus; Vaccination; Retroviridae; AIDS; Vaccine; Immune deficiency; Lentivirus; Infection; Virus; Viral disease; Phase II trial; Phase I trial; Human immunodeficiency virus; Failure
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1086/514209

Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous drug use accounted for 6. Four subjects received placebo, 13 received a complete immunization schedule (⩾3 injections), and 6 were partially immunized (⩽2 injections). There was no significant difference between vaccine recipients and control groups in incidence of HIV-1 infection, virus load, CD4 lymphocyte count, or V3 loop amino acid sequence. In summary, 19 vaccinated subjects acquired HIV-1 infection during phase I and II trials, indicating that immunization with the products described is <100% effective in preventing or rapidly clearing infection. Laboratory analysis suggested that vaccineinduced immune responses did not significantly affect the genotypic or phenotypic characteristics of transmitted virus or the early clinical course of HIV-1 infection.